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Abstract
Objective Hypertrophic obstructive cardiomyopathy
(HOCM) is treated by surgical myectomy or transcoronary
ablationofseptalhypertrophy(TASH).Theaimofthisstudy
wastovisualizethefeasibility,successandshort-termresults
of TASH on the basis of cardiac MRI (CMR) in comparison
with cardiac catheterization and echocardiography.
Methods In this in vivo study, nine patients with HOCM
were treated with TASH. Patients were evaluated by
transthoracic echocardiography, invasive cardiac angiog-
raphy and CMR. Follow-up examinations were carried out
after 1, 3 and 12 months. MR imaging was performed on a
1.5-T scanner. All images were processed using the semi-
automatic Argus software and were evaluated by an
attending thoracic radiologist and cardiologist.
Results The echocardiographic pressure gradient (at rest)
was69.3 ± 15.3 mmHgbeforeand22.1 ± 5.7 mmHgafter
TASH (P\0.01, n = 9). The ﬂux acceleration over the
aortic valve examined (Vmax) was 5.1 ± 0.6 m/s before and
3.4 ± 0.3 m/s after the TASH procedure (P\0.05). Also,
therewas adecrease ofseptum thicknessfrom22.0 ± 1.2to
20.2 ± 1.0 mm (P\0.05) after 6 ± 3 weeks. The inva-
sively assessed pressure gradient at rest was reduced from
63.7 ± 15.2to21.2 ± 11.1 mmHg(P\0.01)andthepost-
extrasystolic gradient was reduced from 138.9 ± 12.7 to
45.6 ± 16.5 mmHg (P\0.01). All differences as well as
the quantity of injected ethanol were plotted against the size
or amount of scar tissue as assessed in the MRI. There was a
statistically signiﬁcant correlation between the post-extra-
systolic gradient decrease and the amount of scar tissue
(P = 0.03, r
2 = 0.5). In addition, the correlation between
the quantity of ethanol and scar tissue area was highly sig-
niﬁcant (P\0.01, r
2 = 0.6), whereas the values for the
gradientdeviation(P = 0.10,r
2 = 0.34),DVmax(P = 0.12,
r
2 = 0.31), as well as the gradient at rest (P = 0.27,
r
2 = 0.17) were not signiﬁcant.
Conclusion TASH was consistently effective in reducing
the gradient in all patients with HOCM. In contrast to the
variables investigated by echocardiography, the invasively
measured post-extrasystolic gradient correlated much bet-
ter with the amount of scar tissue as assessed by CMR. We
conclude that the optimal modality to visualize the TASH
effect seems to be a combination of CMR and the invasive
identiﬁcation of the post-extrasystolic gradient.
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Introduction
Hypertrophic obstructive cardiomyopathy (HOCM) is a
relatively common genetic cardiovascular disease with a
prevalence of *1:500 [1]. Patients with HOCM often
present with symptoms of heart failure and insufﬁcient
response to medical treatment [2–5]. The most frequent
therapy applied to these patients is surgical myectomy
(removing a small amount of myocardium from the basal
interventricular septum) [6–9]. This substantially reduces
the subaortic outﬂow gradient in more than 90% of patients
and results in persistent symptomatic improvement in
about 70–90% [2, 5, 7–10]. In the last few years, minimally
invasive transcoronary ablation of septal hypertrophy
(TASH) by selective transcatheter septal branch injection
of ethanol has shown to reduce substantially outﬂow tract
obstruction in 80–90% and reduction of symptoms in 84–
90% of the treated patients [11–19]. Consequently, TASH
may be an effective alternative to surgery [20–27]. To
avoid collateral damage like right bundle branch block
(RBBB) or high-grade atrioventricular block it is important
to estimate the anatomical conditions before starting the
intervention. Therefore, the purpose of the present study
was to visualize the feasibility, hemodynamical success,
and short term results of TASH on the basis of intracardiac
catheterization, cardiac MRI (CMR), and echocardiogra-
phy before and after the TASH procedure.
Materials and methods
To visualize the feasibility, hemodynamic success, and
short term results of TASH intracardiac catheterization,
CMR and echocardiography were conducted at baseline
and in follow-up studies after 1, 3, and 12 months fol-
lowing the TASH procedure. All patients were monitored
in the intensive or coronary care unit for at least 48 h. ECG
and cardiac enzyme controls were assessed every 4 h until
the CK peak was reached. Before discharge, noninvasive
follow-up included Doppler assessments of the residual
LVOT gradient.
Patient inclusion
TASH was applied to nine patients (median age
62 ± 6 years, six females and three males) with HOCM.
The diagnosis of HOCM was based on the common clinical
and two-dimensional echocardiographic criteria [1].
Obstruction was deﬁned by an LVOT gradient under
resting conditions and after provocation of at least
30 mmHg [1]. Detailed patients’ characteristics are pre-
sented in the Table 1. A written informed consent was
obtained from each patient.
Echocardiographic examination
Transthoracic and transesophageal echocardiography was
performed on Philips Sonos 5500 (Philips Medical Sys-
tems) and recorded on an S-VHS video to allow serial
review and side-by-side comparison of the studies. Standard
probes were used for transthoracic and transesophageal
echocardiography. Basal ventricular septal thickness was
divided from an integrated analysis of M-mode and two-
dimensional echocardiograms. The M-mode echocardio-
grams were derived from direct anatomical visualization of
the two-dimensional images. All measurements were made
according to the recommendations of the American Society
of Echocardiography [28]. The two-dimensional echocar-
diographic images were obtained in the parasternal long-
and short-axis views and apical two- and four-chamber
views using standard transducer positions. For transesoph-
ageal acquisition, the probe was placed in the mid-esoph-
ageal position, where an adequate four-chamber view could
be obtained. Short-axis views were derived from a basal
gastric position. Care was taken to achieve a similar probe
position for the follow-up examinations. Systolic anterior
motion of the mitral valve was deﬁned as mild, moderate or
severe according to Gilbert et al. [29]. Echocardiographic
examinations were conduced at baseline, 6 ± 3 weeks,
3 months, and 1 year after TASH.
TASH procedure
In each case, the gradient at rest and the post-extrasystolic
gradient were measured before and after the procedure.
Table 1 Clinical characteristics of nine patients undergoing catheter-
based treatment for HOCM by TASH
Patient characteristics
Total no. of patients 9
Male/female sex no. 3/6
Age (years) 62 ± 6
Septum thickness (mm) 22.0 ± 1.2
Echocardiographic pressure gradient (mmHg) 69.3 ± 15.3
Echocardiographic ﬂux acceleration (Vmax) (m/s) 5.1 ± 0.6
Invasive gradient at rest (mmHg) 63.7 ± 15.2
Invasive postextrasystolic gradient (mmHg) 138.9 ± 12.7
Ethanol injection (ml) 1.8 ± 0.3
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123Brieﬂy, a suitable proximal branch of the left anterior
descending coronary artery was identiﬁed by a gradient-
guided technique under programmed electrical stimulation.
By using this technique, signiﬁcantly smaller amounts of
ethanol couldbeusedbytitratingtheethanoldoseaccording
to the angiographic washout velocity and real-time mea-
sured reduction of the intraventricular pressure gradient.
Programmed electrical stimulation was used to provoke
prematureventricularbeatsunderreproducibleconditionsto
assess post-extrasystolic potentiation of the gradient. Using
this technique the ﬁxed coupling interval is followed by an
identical duration of the left ventricular ﬁlling period and a
constant magnitude of the subsequently provoked gradient
which correlates signiﬁcantly with the gradient after physi-
cal exercise [23, 30]. Ethanol was injected only in case of a
clear reduction of the gradient during testing the effect of a
transient balloon occlusion of the septal vessel.
CMR investigation
CMR was carried out 10 ± 4 weeks after TASH. MR
imaging was performed on a 1.5-T scanner (Magnetom;
Siemens, Germany) with 40-mT/m maximum gradient
strengthandaphasedarraybodycoil.Investigationtimewas
about 30–40 min. Patients were studied in a supine position
with breath-holding-technique. Short-axis cine MRI of the
entire left ventricle from the base to the apex was performed
for the analysis of cardiac mass and function. Heart rate,
vectorcardiogram and blood pressure were monitored.
The left ventricular function was assessed by a seg-
mented two-dimensional electrocardiographically triggered
fast low-angle shot-pulse sequence in the cine mode (TR
23.8 ms, TE 1.49 ms, ﬂip angle 59, basic resolution
256 9 256, voxel size 2.0 mm 9 1.6 mm 9 5 mm, slice
thickness 5 mm, chronological resolution 50 ms, ﬁeld of
view phase 81.3%, phase resolution 79%, distance factor
20% and ﬁeld of view reading up to 500 mm). The number
of cardiac phases imaged depended on the heart rate.
Typically, 16 phases per cardiac cycle were obtained.
Three short-axis planes were obtained; slice positions were
taken from the cine MR imaging data set. The basal slice
was the ﬁrst to show circumferential myocardium at both
diastole and systole. The apical slice was the last to show
the intracavity blood pool in all phases over the cardiac
cycle. The mid-ventricular slice was positioned halfway
between the basal slice and the apical slice.
The left ventricular ejection fraction (LVEF) was esti-
mated from the short-axis planes. Therefore, a segmented
two-dimensional electrocardiographically triggered fast
low-angle shot-pulse sequence was used during breath-
holding (TR 23.8 ms, TE 1.49 ms, ﬂip angle 59, basic
resolution 256 9 256, voxel size 2.0 mm 9 1.6 mm 9
5 mm, slice thickness 5 mm, chronological resolution
50 ms, ﬁeld of view phase 81.3%, phase resolution 79%,
distancefactor20%andﬁeldofviewreadingupto500 mm).
The numberof cardiac phases imaged depended on the heart
rate.
Image analysis
Tagged images were processed using the semiautomatic
ARGUS software (version 2004 A; Siemens, Germany)
and were evaluated by an attending thoracic radiologist and
cardiologist. The area of interest was the ventricular sep-
tum and the subaortic region. The endo- and epicardial
contours were deﬁned in the end-diastolic frame and the
software then detected the tag grid using an afﬁne plus
anisotropic radial scaling transform algorithm. The grid
was adapted to each of the acquired images from the end-
diastolic to the end-systolic frame, mass, left and right
ventricular ejection fraction. If necessary, manual correc-
tion was performed by moving, adding, or deleting tag
intersections. Evaluation time for tracking the tag inter-
sections of one slice was about 30 min.
Left ventricular function and mass was also analyzed.
After the determination of the end-diastolic and end-sys-
tolic frame on the ﬁrst basal slice to show circumferential
myocardium at both diastole and systole, the endocardial
and epicardial contours were traced manually by two
investigators. The papillary muscles were included in the
measured ventricular volume. To account for body height
and mass, indexes were calculated related to 1 m
2 of body
surface area for volumes and masses. Parameters of global
function of the left ventricle were end-diastolic and end-
systolic volume index and ejection fraction. The ventricu-
lar mass index was obtained by the multiplication of the
mean wall volume of the end-diastolic and the end-systolic
frames and the speciﬁc weight of cardiac muscle (1.05
g/mL). All volumes were calculated automatically by sum-
ming the areas in the entire series of short-axis cine images.
Data analysis and statistics
All data are expressed as mean ± SEM. Student’s paired t
test was used to test for signiﬁcance. P\0.05 was con-
sidered signiﬁcant. A linear regression analysis was used
for comparing gradient data and ethanol injection with
myocardial scar tissue. GraphPad Prism 5 was used to
perform the regression analysis and Microsoft Excel was
used in the case of paired t test of normal distributed data.
Results
TASH was highly effective in improving hemodynamic
and anatomic conditions. Figure 1 shows the differences in
Clin Res Cardiol (2010) 99:359–368 361
123LVOT gradient, ﬂux acceleration (Vmax), septum thickness,
pressure gradient at rest, post-extrasystolic gradient before
and after TASH, as well as the corresponding scar tissue.
The echocardiographic pressure gradient could be
signiﬁcantly reduced by the TASH intervention. The
LVOT gradient was reduced from 69.3 ± 15.3 to
22.1 ± 5.7 mmHg(Fig. 1a,n = 9patientseach,P\0.01).
Moreover, Vmax was decreased from 5.1 ± 0.6 to
3.4 ± 0.3 m/s (Fig. 1b, P\0.05). There was a decrease of
septum thickness from 22.0 ± 1.2 to 20.2 ± 1.0 mm
(Fig. 1, P\0.05).
After the successful TASH procedure the scar tissue was
appraised by CMR. The mean scar tissue area was
5.0 ± 0.3 cm
2 (Fig. 1d). The intracardiac catheter delivers
the corresponding gradients in situ. The invasively assessed
LVOT pressure gradient at rest was decreased from
63.7 ± 15.2 to 21.2 ± 11.1 mmHg (Fig. 1e, P\0.01),
and the post-extrasystolic gradient was reduced from
138.9 ± 12.7 to 45.6 ± 16.5 mmHg (Fig. 1f, P\0.01).
To further visualize the operability and success of
TASH the echocardiographic and invasive measurements
were correlated with the accordant CMR scar tissue area
into the ventricular septum in the subaortic region. Figure 2
demonstrates the correlation between the scar size and the
echocardiographically and invasively assessed parameters.
Figure 2d demonstrates a signiﬁcant correlation between
the scar size and the invasively measured post-extrasystolic
gradient reduction (P\0.05, r
2 = 0.5), whereas the
values for the echocardiographic gradient deviation
(Fig. 2a, P = 0.10, r
2 = 0.34), DVmax (Fig. 2b, P = 0.12,
r
2 = 0.31), as well as the invasive gradient at rest (Fig. 2c,
P = 0.27, r
2 = 0.17) were not signiﬁcant. To evaluate the
different effects of varying ethanol dosing within the pro-
cedure, the CMR scar tissue area was correlated with the
quantity of injected ethanol. Our data showed a signiﬁcant
correlation between the amount of ethanol and the scar
tissue (Fig. 3, P\0.01, r
2 = 0.6).
Discussion
In 1995, Sigwart et al. [12] were the ﬁrst to describe the
effect of occluding a septal perforator artery with ethanol on
the pressure gradient in HOCM. This procedure provoked a
localized septal infarction and was referred to as nonsur-
gical septal reduction therapy (NSRT). Subsequently, two
German centers reported extensive experience with many
hundreds of patients [13, 31]. Seggewiss et al. [31] have
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123referred to the procedure as percutaneous transluminal
septal myocardial ablation (PTSMA), whereas Gietzen
et al. [13, 27] have called the procedure transcoronary
ablation of septal hypertrophy (TASH). There is enough
evidence to show that the amount of ethanol used and the
number of septal perforator arteries ablated determine the
height of the creatine kinase (CK) rise, the degree of acute
gradient reduction (Fig. 4) and the incidence of complete
heart block and mortality [13, 17, 27, 31]. The introduction
of myocardial contrast echocardiography by Faber et al.
[16] allows for the correct identiﬁcation of the appropriate
septal perforator to be occluded and the avoidance of
occluding septal perforators that supply distant areas of the
myocardium such as the papillary muscles or the free wall
of the left or right ventricle. However, it has been shown
that the amount of septum reduction increases further with
time after TASH [32]. The observation that there is further
gradient reduction in the year following the procedure has
led to a less aggressive approach in terms of the amount of
ethanol used and the number of vessels ablated during the
procedure with a resulting decrease in the incidence of heart
block [13, 17, 20, 27, 31, 32].
The TASH procedure is a promising nonsurgical tech-
nique for the reduction of symptoms and the LVOT gra-
dient in HOCM. Several studies have shown clinical
success rates with TASH application, varying from 90 to
100% [13, 15, 18, 20, 31, 32]. This is in line with our
ﬁndings. Our results demonstrate a clinical success rate
deﬁned as a reduction of the echocardiographic LVOT
gradient at rest, septum thickness, invasively assessed
gradient at rest and gradient after stimulation of 100%
(Fig. 1). The invasive measurements showed a signiﬁcant
decrease of the basal LVOT gradient at rest and also of the
post-extrasystolic gradient after the TASH procedure
(Figs. 1, 4). The echocardiographic examination of the
LVOT gradient under basal conditions, the maximal ﬂux
acceleration over the aortic valve and septum size before
and after TASH treatment conﬁrms these results (Fig. 1).
We could show a TASH-associated improvement in all
examinations. Consequently, TASH was highly effective in
improving hemodynamic and anatomic conditions. Fur-
thermore, the TASH procedure has some advantages in
comparison to myectomy surgery. These advantages
include: the avoidance of cardiopulmonary bypass with
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123attendant risks, especially in elderly patients, as well as a
shorter hospitalization period. Although two large German
studies reported longer hospital residencies for supervision
for delayed heart block [13, 31], a shorter recovery time
and less expenses were recorded.
On the other hand, the advantages of myectomy surgery
include: more immediate and complete relief of resting and
provoked obstruction and concomitant mitral regurgitation,
as well as smaller incidences of complete heart block,
requiring a pacemaker. There are excellent long-term
results with no risk of coronary dissection or unwanted
myocardial infarction. There is no evidence in long-term
studies that myectomy is arrhythmogenic, has ability to
deal with concomitant problems such as mid-ventricular
Fig. 4 A 50-year-old male
patient with HOCM and TASH.
a Angiography protocol before
TASH showing a post-
extrasystolic gradient at rest of
150 mmHg. b After the
procedure the post-extrasystolic
gradient is documented as
maximal 40 mmHg
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123obstruction, constricting muscle bridges over the left
anterior descending coronary artery, and aortocoronary
bypass surgery. It does not cause right ventricular outﬂow
obstruction, mitral valve repair or replacement for addi-
tional valvular problems, and concerning a small but sig-
niﬁcant amount of patients, it is not able to carry out NSRT
for technical reasons, and NSRT may be less effective in
younger patients with thicker septum [33] and in other
speciﬁc circumstances.
There is still a considerable debate on the optimal pro-
cedureinthemanagementofsubaorticobstructiveHCM.On
the one hand the ambition of TASH is the reduction of
symptoms and the LVOT gradient in HOCM. On the other
hand it is essential to reduce the collateral complications of
the nonsurgical procedure like RBBB (in almost 50% of the
patients) and high-grade atrioventricular block requiring
permanent pacing in 10% [34]. Therefore, it is important to
create asmall-sizedinfarction-area.TheroleofCMR wasto
estimate the anatomical conditions before starting the
intervention and to clarify the broadening of scar tissue. In
our opinion, the current role and future potential of CMR in
TASH has not been investigated sufﬁciently. It is accepted
thatCMRisthe goldstandard imaging tooltoaccess cardiac
masses or to measure cardiac scar tissue [35–39]. Further-
more, CMR has an outstanding role in ischemia diagnostic
and coronary artery disease (CAD) [40–49]. To our knowl-
edge this is the ﬁrst study that shows a direct correlation of
the CMR scar tissue and the effectiveness of TASH.
One aim of this study was to evaluate the ideal diagnostic
imaging modality to illustrate the effectiveness of the
TASH procedure. Another aim was to assess if the broad-
ening of the infarction area correlates with the reduction of
the LVOT gradient. After the successful TASH procedure
the scar tissue was appraised by CMR and the infarction
area was correlated with the decrease of the LVOT gradient
the septum downsizing and the ethanol injection. Figure 2
shows a correlation between each examination and the
corresponding scar tissue. There was no signiﬁcant corre-
lation between the echocardiographic investigations and the
corresponding scar tissue into the CMR investigation.
Consequently, echocardiography may not be able to visu-
alize the effectiveness of TASH signiﬁcantly. Concerning
the invasive measurements, Fig. 2c also delivers a nonsig-
niﬁcant result for the correlation of the angiographic LVOT
gradient at rest and the imaged infarction area. In Fig. 2d
the post-extrasystolic gradient is plotted against the scar
tissue. There was a statistical signiﬁcant correlation
between the different investigation methods (P = 0.03,
r
2 = 0.5). Furthermore, our results suggest some answers in
the remaining areas of uncertainty concerning the different
effects of varying ethanol dosing within TASH. Veselka
et al. [50], compared the effect of a ‘‘high dose’’
(2.8 ± 0.6 ml) versus a ‘‘low dose’’ (1.5 ± 0.4 ml) of
ethanol, resulting in CK peaks of about six- versus ninefold
above their upper reference value of 0.4 Kat/l. As the main
conclusion, no difference was found with respect to
hemodynamic efﬁciency during short-term follow-up in 42
patients. This is in concert with several other studies which
suggest, that a correctly placed ablation lesion, releasing a
CK peak of ﬁve- to nine-fold, should be high enough to
substantially reduce or eliminate the LVOT obstruction
during a 12-month local remodeling process [27, 51, 52]. In
our study, the mean amount of ethanol injected was
1.8 ± 0.3 ml (Table 1). The results of our study show a
signiﬁcant correlation between the amount of injected eth-
anol and scar tissue investigated by CMR (Fig. 3, P = 0.01,
r
2 = 0.6). Consequently, these data underline the out-
standing importance of the correctly placed TASH proce-
dure. Our analysis clariﬁes the ability of CMR to deliver a
direct in vivo evaluation of the ethanol associated infarction
area (Figs. 5, 6). Thus, it offers an independent alternative
to laboratory testing and other imaging techniques.
Fig. 5 An 82-year-old female
patient with HOCM. MRI at
four-chamber view (a, c, e) and
at three-chamber view (b, d, f)
before (a, b) and after TASH
(c, d, e, f). a, c and e In each
case late enhancement pictures
after intravenous contrast
medium injection. In the four-
chamber view conﬁrmation of
scar tissue in the septum area
(c, e). b, d and f in each case
pictures in cine mode in the
three-chamber view with SAM
phenomenon which impresses
slightly declining
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123This indicates that a combined technique of invasive
measurements and noninvasive CMR is ideally suited to
assess the efﬁciency of TASH in ventricular hypertrophy
and remodeling, which may allow a reduction in sample
size to show clinically relevant effects. A comprehensive
functional assessment is possible by CMR because of its
capability to measure the ﬂow velocity and the ﬂow vol-
ume, which are the basic requirements to quantify lesion
severity in a heart disease, which was formerly the main
focus of echocardiography (Fig. 7)[ 35, 36, 40]. Another
important advantage of CMR over other imaging methods
that are used to assess myocardial viability is that it shows
the transmural extent of viable myocardium (Fig. 5)[ 41].
This leads to the possibility of visualizing the ethanol
determined infarction area as scar tissue. Furthermore,
major technical advances have considerably improved
acquisition speed and image quality thus making CMR a
useful tool for the evaluation of patients with ischemic
heart disease [42–49].
Our study has several limitations. It has to be considered
that there is only a relative small study population which
leads to high range of individual variability. Probably,
some results would have reached statistical signiﬁcant
correlation with a greater amount of patients. Patients were
Fig. 6 A 68-year-old female
patient with HOCM. a septum
nose before and b after the
TASH procedure, with
reduction of the marked areas
Fig. 7 A 78-year-old male
patient with each MR
investigation into cine mode
before TASH. a SAM
phenomenon, b, c and d.
Measurement of dimensions,
b at three-chamber view, c at
short axis (end-systolic) and d at
short axis (end-diastolic)
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123not assigned randomly. Larger studies with more patients
have to be conducted. The M-mode measurements of left
atrial and left ventricular dimensions may not sample
exactly maximum and minimum wall thickness, may be
subject to angle errors, and were not performed blinded
with respect to treatment status.
We come to the conclusion that CMR offers a poten-
tially more accurate noninvasive technique for in vivo
comparison of scar tissue than echocardiography. Further-
more, CMR provides images with high spatial resolution,
free of geometric constraints, as well as precise volumetric
quantiﬁcation of abnormalities and direct anatomical cor-
relation (Figs. 5, 6). We conclude that, the optimal
modality to visualize the TASH effect seems to be a
combination between CMR-imaging and the invasive
identiﬁcation of the post-extrasystolic gradient.
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